Please wait a minute...
2TMR Integrative Medicine  2019, 3: e19004.       DOI: 10.12032/TMRIM201903004
    
Pathogenesis and treatment status of adenomyosis complicated with infertility
Hua Wang1, Chun-Hua Cao1, Yan Chen1, Saili Wang1, Qin Wang1,*()
1Taizhou Hospital of Traditional Chinese Medicine, Affiliated to Nanjing University of Traditional Chinese Medicine, Taizhou, China.
Download: HTML     PDF(426KB)
Export: BibTeX | EndNote (RIS)      

Highlights:

The treatment options for patients of AD with infertility should follow the principle of individual treatment and choose the most appropriate method based on the specific conditions of the hospital.

Abstract

Adenomyosis (AD) refers to the endometrium (including glands and stroma) into myometrium growth of pathological changes, with the delay of women's childbearing age, the patients with AD-associated infertility increased significantly. Although scholars disagreed about the effect of AD on infertility, more and more evidence showed that AD was closely related to the structural and functional defects of the eutopic endometrium and myometrial junctional zone (MJZ), which may lead to embryo implantation failure and infertility. With the rapid development of imaging technology, the accuracy of diagnose AD has been enhanced, more and more infertility patients were diagnosed with AD. At the same time, a series of pathogenic hypothesis have been proposed to explain the relationship between AD. In addition, AD may influence the patient’s reproductive function by affecting sperm transport, embryo implantation, altering uterine peristalsis, influencing the structure and function of endometrium, and changing the intrauterine environment. At present, the treatment of AD-associated infertility is similar to the treatment of AD. The commonly used treatment methods include drug therapy, conservative operative treatment, drug combination surgery, and Chinese medicine treatment and so on. The clinical and experimental studies of AD complicated with infertility and its possible pathogenesis and treatment in recent years are reviewed in this article.



Key wordsAdenomyosis      Infertility      Pathogenesis      Treatment      Endometrium     
Published: 21 February 2019
Fund:  Funding:This study was supported in part by grants from the “333 project” project of Jiangsu province (BRA2016183)
Corresponding Authors: Wang Qin   
E-mail: wangqin322@126.com
Cite this article:

Hua Wang, Chun-Hua Cao, Yan Chen, Saili Wang, Qin Wang. Pathogenesis and treatment status of adenomyosis complicated with infertility. 2TMR Integrative Medicine, 2019, 3: e19004.  

URL:

https://www.tmrjournals.com/im/EN/10.12032/TMRIM201903004     OR     https://www.tmrjournals.com/im/EN/Y2019/V3/IVolume 3/88888

1.   Dunselman GA, Vermeulen N, Becker C, et al. ESHRE guide-line: management of women with endometriosis. Hum Reprod 2014, 29: 400-412.
2.   Xie X, Gou WL.Obstetrics and gynecology. Beijing: People’s Medical Publishing House, 2013.
3.   Maheshwari A, Gurunath S, Fatima F, et al. Adenomyosis and subfertility: a systematic review of prevalence, diagnosis, treatment and fertility outcomes. Hum Reprod Update 2012, 18: 374-392.
4.   Tasuku H, Yin MK, Apostolos K, et al. The impact of adenomyosis on women’s fertility. Obstetrical and Gynecological Survey 2016, 71: 557-568.
5.   Wei RR, Huang XF, Li J, et al. The value and pathological analysis of MRI examination of adenomyosis. Clinical medical research and practice 2017, 11: 135-136.
6.   Piver P.Uterine factors limiting ART coverage. J Gynecol Obstet Biol Reprod (Paris) 2005, 34: 5S30-5S33.
7.   Bulletti CC, de Ziegler D. Uterin ontractility and embryo implantation. Curr Opin Obstet Gynecol 2006, 18: 473-484.
8.   Mehasseb MK, Bell SC, Brown L, et al. Phenotypic characterisation of the inner and outer myometrium in normal and adenomyoticuteri. Gynecol Obstet Investt 2011, 71: 217-224.
9.   Bai CH, Shuang T, Wang M.Endometriosis and fertility problems in patients with adenomyosis. Chin J Practical Gynecology Obstetrics 2013, 29: 524-527.
10.   Kissler S, Hamscho N, Zangos S, et al. Uterotubal transport disorder in adenomyosis and endometriosis-a cause for infertility. Br J Obstet Gynaecol 2006, 113: 902-908.
11.   Garavaglia E, Audrey S, Annalisa I, et al. Adenomyosis and its impact on women fertility. Iran J Reprad Med 2015, 13: 327-336.
12.   Ota H, Tanaka T.Stromal vascularization in the endometrium during adenomyosis. Microsc Res Tech 2003, 60: 445-449.
13.   Li T, Li YG, Pu DM.Matrix metalloproteinase-2 and -9 expression correlated with angiogenesis in human adenomyosis. Gynecol Obstet Invest 2006, 62: 229-235.
14.   Wicherek L.Alterations in RCAS1 serum concentration levels during menstrual cycle in patients with uterine leiomyoma and lack of analogical changes in adenomyosis. Gynecol Obstet Invest 2009, 67: 195-201.
15.   Yang JH, Wu MY, Chang DY, et al. Increased interleukin-6 messenger RNA expression in macrophage co-cultured endometrial stromal cells in adenomyosis. Am J Reprod Immunol 2006, 55: 181-187.
16.   Ulukus M, Ulukus EC, Seval Y, et al. Expression of interleukin-8 receptors in patients with adenomyosis. Fertil Steril 2006, 85: 714-720.
17.   Wang F, Li H, Yang Z, et al. Expression of interleukin-10 in patients with adenomyosis. Fertil Steril 2009, 91: 1681-1685.
18.   Oh NJ, Ryu KY, Jung CN, et al. Expression of endothelial nitricoxide synthase in the uterus of patients with leiomyoma or adenomyosis. Obstet Gynaecol Res 2013, 39: 536-542.
19.   Devlieger R, D'Hooghe T, Timmerman D. Uterine adenomyosis in the infertility clinic. Hum Reprod Update 2003, 9: 139-147.
20.   Fischer CP, Kayisili U, Taylor HS.HOXA10 expression is decreased in endometrium of women with adenomyosis. Fertil Steril 2011, 95: 1133-1136.
21.   Xiao Y, Sun X, Yang X, et al. Leukemia inhibitory factor is dysregulated in the endometrium and uterine flushing fluid of patients with adenomyosis during implantation window. Fertil Steril 2010, 94: 85-89.
22.   Morelli M, Rocea ML, Venturella R, et al. Improvement in chronic pelvic pain after gonadotropin releasing hormone analogue (GnRH-a) administration in premenopausal women suffering from adenomyosis or endometriosis: a retrospective study. Gynecol Endocrinol 2013, 29: 305-308.
23.   Kim YA, Kim MR, Lee JH, et al. Gonadotropin-releasing hormone agonist reduces aromatase cytochrome P450 and cyclooxygenase-2 in ovarian endometrioma and eutopic endometrium of patients with endometriosis. Gynecol Obstet Invest 2009, 68: 73-81.
24.   Khan KN, Kitajima M, Hiraki L,et al. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyoeis and uterine myoma after GnRH-a agonist therapy. Hum Reprod 2010, 25: 642-653.
25.   Tremellen K, Thalluri V.Impact of adenomyosis on pregnancy rates in IVF treatment. Reprod Biomed Online 2013, 26: 299-300.
26.   Xiao Y, Sun X, Yang X, et al. Leukemia inhibitory factor is dysregulated in the endometrium and uterine flushing fluid of patients with adenomyosis during implantation window. Fertil Steril 2010, 94: 85-89.
27.   Igarashi M, Abe Y, Fukuda M, et al. Novel conservative medical therapy for uterine adenomyosis with a danazol-loaded intrauterine device. Fertil Steril 2000, 74: 412-413.
28.   Brown J, Kives S, Akhtar M .Progestagens and anti-progestagens for pain associated with endometriosis.Cochrane Database Syst Rev2012, 3: CD002122.
29.   Levy G, Dehaene A, Laurent N, et al. An update on adenomyosis. Diagn Interv Imaging 2013, 94: 3-25.
30.   Nagata C, Yanagida S, Okamoto A, et al. Risk factors of treatment discontinuation due to uterine bleeding in adenomyosis patients treated with dienogest. Obstet Gynaecol Res 2012, 38: 639-644.
31.   Badawy AM, Elnashar AM, Mosbah AA.Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: a randomized controlled trial. Acta Obstet Gynecol Scand 2012, 91: 489-495.
32.   Streuli I, Dubuisson J, Santulli P, et al. An update on thepharmacological management of adenomyosis. Expert Opin Pharmaeother 2014, 15: 2347-2360.
33.   Wang PH, Fuh JL, Chao HT, et al. Is the surgical approach beneficial to subfertile women with symptomatic extensive adenomyosis? J Obstet Gynaecol Res 2009, 35: 495-502.
34.   Osada H, Silber S, Kakinuma T, et al. Surgical procedure to conserve the uterus for future pregnancy in patients suffering from massive adenomyosis. Reprod Biomed Online 2011, 22: 94-99.
35.   Wang PH, Liu WM, Fuh JL,et al. Comparison of surgery alone and combined surgical-medical treatment in the management of symptomatic uterine adenomyoma. Fertil Steril 2009, 92: 876-885.
36.   Lu HM, Huang Y, Hu Y.Treatment of 30 cases of adenomyosis with acupuncture combined with modified Siwu Decoction. Journal of Shandong University of Traditional Chinese Medicine 2017, 1: 42-44.
[1] Teng Huang, Ling-Jing Zhang, Li-Na Zhang, Zhi-Yong Zhao, Bin Hao. A review of the treatment of ankylosing spondylitis from liver and kidney[J]. 2TMR Integrative Medicine, 2019, 3(Volume 3): 88888-e19009.
[2] Jia Wang, Zhu Yang, Feng-Xi Long, Jin-Lin Wu, Ting Yu, Xian-Man Wei, Xun Liu, Dong-Xin Tang. Prevention and treatment of traditional Chinese medicine for elderly patients with colorectal cancer[J]. 2TMR Integrative Medicine, 2019, 3(Volume 3): 88888-e19016.
[3] Meng-Lei Li, Shan-Fu Chen, Ying-Qiang Zhao. Non-pharmacological therapy of TCM for the treatment of essential hypertension[J]. 2TMR Integrative Medicine, 2019, 3(1-12): 88888-e19010.
[4] Bo-Yong Qiu, Yong-Xia Wang, Zuo-Ying Xing, Bin Li, Ming-Jun Zhu, Peng Chen, Jia Zheng. Analysis of 610 cases inpatients with chronic heart failure[J]. 2TMR Integrative Medicine, 2018, 2(2): 87-91.
[5] Jia Long, Zhang Hua. Discussion on the thinking innovation of the “Treatment based on syndrome differentiation” according to “Precision medical”[J]. 2TMR Integrative Medicine, 2018, 2(1): 48-53.
[6] Ming-shan Liu, Ya-Mo . Advances in the research of high myopia treatment[J]. 2TMR Integrative Medicine, 2017, 1(3): 124-129.